1 day ago
Just in from The World Congress of Dermatology 2019 in Milan:
It is Ruxolitinib the name of the newdrug that has the potential to change the way vitiligo is treated. Not only it is effective at repigmenting the skin, but it has an excellent safety profile, said David Rosmarin, MD- Dermatologist from Boston who lead this phase 2 clinical trial and just presented the result of this study 4 days ago at the congress.
There is no known cause of vitiligo, a disease in which the immune system attacks pigment cells in the body. Vitiligo may range from mild to severe and can be found anywhere on the body, although it typically affects exposed areas, such as the face and hands. While vitiligo is not evident at birth, about half of vitiligo patients contract the disease before age 20. Approximately 50 million people one percent of the worldwide population are affected by vitiligo, including musical artist Michael Jackson, and model Winnie Harlow. Vitiligo affects all ethnic groups equally, but is more evident in ethnic minorities with darker skin. No FDA-approved re-pigmenting treatments for vitiligo currently exist.
Current treatments such as phototherapy, topical corticosteroids, and calcineurin inhibitors have limited efficacy.
skinspiration vitiligo vitiligotreatment pengobatanvitiligo dokterspesialiskulit indonesiandermatologist